New drug KarXT tested in breast milk: what it means for nursing moms
NCT ID NCT07257120
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how much of the drug KarXT (xanomeline/trospium chloride) gets into the breast milk and blood of 10 healthy women who were breastfeeding. The goal was to measure drug levels and estimate how much an infant might be exposed to. The results will help guide safe use of KarXT during breastfeeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Xanomeline/trospium chloride (KarXT)
- What this could lead to
- If successful, this study could help doctors understand whether KarXT is safe for breastfeeding mothers and their infants.
- What could go wrong
- This is a small, early-stage study in healthy volunteers, not patients. Results may not apply to all women or guarantee infant safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0001
Las Vegas, Nevada, 89113-2246, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults